Evidence map›Paper›PMID 41376630›Full record

ReviewFrontiers in immunology2025

Inflammatory factors collaboratively link

Mingze Zhang, Ade Su, Houji Song, Siyu Zhang, Yuan Deng, Wutang Jing, Jin Guo, Weipeng Zhan, Yuntao Ma, Ming Hu

Abstract readReview
In one paragraph

Review in Frontiers in immunology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed.

  1. Article
  2. Review
  3. Review
  4. Article
  5. Article
  6. Review
  7. Article
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Mingze Zhang *Department of General Surgery, Gansu Provincial Hospital, Lanzhou, China.
Ade Su *The Second Clinical School of Medicine, Lanzhou University, Lanzhou, China.
Houji Song *Department of General Surgery, Gansu Provincial Hospital, Lanzhou, China.
Siyu Zhang *Department of General Surgery, Gansu Provincial Hospital, Lanzhou, China.
Yuan DengDepartment of General Surgery, Gansu Provincial Hospital, Lanzhou, China.
Wutang JingDepartment of General Surgery, Gansu Provincial Hospital, Lanzhou, China.
Jin GuoDepartment of General Surgery, Gansu Provincial Hospital, Lanzhou, China.
Weipeng ZhanDepartment of General Surgery, Gansu Provincial Hospital, Lanzhou, China.
Yuntao MaDepartment of General Surgery, Gansu Provincial Hospital, Lanzhou, China.
Ming HuDepartment of General Surgery, Gansu Provincial Hospital, Lanzhou, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Long-term inflammatory reaction may promote gastric cancer initiation and development through multiple mechanisms. Recent studies have demonstrated that inflammatory mediators play a crucial role in the transition from gastritis to gastric cancer. Pro-inflammatory cytokines, chemokines, and other signaling molecules interact and synergistically regulate gastric epithelial cell proliferation, apoptosis, migration, and invasiveness, thereby promoting tumorigenesis. Specifically, interleukins activate immune cells, induce the secretion of inflammatory mediators, and maintain local immune responses; however, in the context of cancer, they exhibit a dual role by both enhancing anti-tumor immunity and driving tumor progression. Tumor necrosis factor amplifies immune responses by stimulating the production of pro-inflammatory cytokines, yet excessive or chronic Tumor necrosis factor activity is a hallmark of autoimmune diseases. Interferons initiate antiviral responses, modulate immune cell functions, and influence the inflammatory cascade. Chemokines primarily mediate the recruitment of immune cells to sites of infection, inflammation, or injury, but also play key roles in immune evasion and tumor immune regulation. This review summarizes the cooperative roles of these inflammatory mediators in the progression from gastritis to gastric cancer and discusses their potential as therapeutic targets. A better understanding of these mechanisms may facilitate the development of novel strategies for the prevention and treatment of gastric cancer.

Indexed as

GastritisHelicobacter InfectionsHelicobacter pyloriInflammation MediatorsStomach NeoplasmsAnimalsCytokinesHumansInflammationCytokinesInflammation Mediatorsgastric cancergastritisHelicobacter pyloriinflammatory factorstumor micro environment

Identifiers

PMID41376630
PMCPMC12687861

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.